CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
This Quarter Return
+25.89%
1 Year Return
+37.91%
3 Year Return
+125.34%
5 Year Return
–
10 Year Return
–
AUM
$6.42M
AUM Growth
+$6.42M
(-93%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-1,690.57%
Top 10 Holdings %
Top 10 Hldgs %
78.79%
Holding
21
New
4
Increased
–
Reduced
11
Closed
6
Top Buys
| 1 |
Rocket Pharmaceuticals
RCKT
|
$439K |
| 2 |
IGMS
IGM Biosciences
IGMS
|
$353K |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$287K |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$260K |
Top Sells
| 1 |
AbbVie
ABBV
|
$15.4M |
| 2 |
Fate Therapeutics
FATE
|
$13.7M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$13.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
$12.5M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$9.9M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BioMarin Pharmaceuticals
BMRN
$11.3B
| $940K | 14.65% |
10,719
-154,462
| -94% | -$13.5M |
|
|
2
Vertex Pharmaceuticals
VRTX
$103B
| $729K | 11.36% |
3,085
-41,904
| -93% | -$9.9M |
|
|
3
Bristol-Myers Squibb
BMY
$96.5B
| $703K | 10.96% |
11,327
-201,987
| -95% | -$12.5M |
|
|
4
AbbVie
ABBV
$374B
| $501K | 7.81% |
4,676
-143,763
| -97% | -$15.4M |
|
|
5
Rocket Pharmaceuticals
RCKT
$350M
| $439K | 6.84% |
+8,000
| New | +$439K |
|
6
Teladoc Health
TDOC
$1.35B
| $389K | 6.06% |
1,944
-19,556
| -91% | -$3.91M |
|
7
IQVIA
IQV
$31.2B
| $375K | 5.84% |
2,094
-37,338
| -95% | -$6.69M |
|
|
IGMS
8
DELISTED
IGM Biosciences
IGMS
| $353K | 5.5% |
+4,000
| New | +$353K |
|
|
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $322K | 5.02% |
2,788
-49,700
| -95% | -$5.74M |
|
10
TG Therapeutics
TGTX
$4.72B
| $304K | 4.74% |
5,847
-89,153
| -94% | -$4.64M |
|
11
Neurocrine Biosciences
NBIX
$14.1B
| $296K | 4.61% |
3,089
-24,911
| -89% | -$2.39M |
|
|
12
Fate Therapeutics
FATE
$119M
| $295K | 4.6% |
3,240
-150,057
| -98% | -$13.7M |
|
|
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $287K | 4.47% |
+3,740
| New | +$287K |
|
|
14
Alnylam Pharmaceuticals
ALNY
$58.6B
| $260K | 4.05% |
+2,000
| New | +$260K |
|
|
TBIO
15
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $223K | 3.48% |
12,091
-215,628
| -95% | -$3.98M |
|
16
Arcus Biosciences
RCUS
$1.15B
| – | – |
-171,982
| Closed | -$2.95M |
|
17
Revolution Medicines
RVMD
$7.39B
| – | – |
-81,000
| Closed | -$2.82M |
|
|
ACCD
18
DELISTED
Accolade, Inc. Common Stock
ACCD
| – | – |
-50,000
| Closed | -$1.94M |
|
|
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-238,151
| Closed | -$1.94M |
|
|
CBAY
20
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-278,416
| Closed | -$2.02M |
|
|
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-42,186
| Closed | -$5.75M |
|